This indefinite delivery contract (IDC) was awarded by the Centers for Disease Control and Prevention (CDC) to Glaxosmithkline, LLC, a pharmaceutical company, to provide pediatric vaccines for the Vaccines for Children (VFC) program. The 5-year, $1.35 billion IDC will run from April 1, 2025 through March 30, 2026, with the option to extend. It was competitively awarded under an unrestricted solicitation, with no small business set-aside. Glaxosmithkline will be required to provide standard commercial pediatric vaccines, with delivery to CDC distribution centers within 15 working days. The contract aims to support immunization efforts for eligible children, including those who are Medicaid-eligible, uninsured, American Indian/Alaska Native, or have insurance that does not cover vaccines. Glaxosmithkline has provided a range of pharmaceutical products and services to federal agencies in the past, including vaccines, antiviral medications, and vaccine adjuvants. This IDC allows the CDC to leverage VFC and Section 317 vaccine purchase funds to obtain vaccines at discounted prices to support their immunization programs.
The IDC has a not-to-exceed ceiling value of $1.35 billion and includes task orders specifying quantities and delivery timelines based on public health requirements. Glaxosmithkline must have FDA licensing, the ability to provide vaccines with a minimum 12-month shelf life, and electronic data interchange capabilities to interface with the CDC's Vaccine Tracking System. The place of performance is primarily the company's facilities in North Carolina, with distribution through CDC centers in Mississippi, Colorado, and Kentucky.
Generated 3/25/25, 9:48 AM